Clinical trial
A Phase 2 Study to Evaluate the Safety and Efficacy of Escalated and Fixed Doses of VS-505(AP301) in Comparison With Sevelamer Carbonate to Treat Hyperphosphatemia in Chronic Kidney Disease Patients Receiving Hemodialysis
NCT04551300 is registered in ClinicalTrials.gov with Shanghai Alebund Pharmaceuticals Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Safety and Efficacy of Escalated and Fixed Doses of VS-505(AP301) in Comparison With Sevelamer Carbonate to Treat Hyperphosphatemia in Chronic Kidney Disease Patients Receiving Hemodialysis
- Lead sponsor
- Shanghai Alebund Pharmaceuticals Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 13, 2020
- Completion date
- October 15, 2022
- Enrollment
- 158 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.